Betacream

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Betacream

What is Betacream? (Classification and Composition)

Property Description
Active Ingredients Betamethasone Dipropionate, Gentamicin Sulfate
Form Cream (Topical Preparation)
Pharmacological Class Corticosteroid-Antibiotic Combination
Origin Synthetic
General Purpose Managing inflammatory skin conditions with bacterial risk

What Type of Medicine is Betacream?

Betacream is a potent combination medication formulated as a topical pharmaceutical preparation for external use on the skin. It is classified as a Corticosteroid-Antibiotic Combination due to its two active ingredients, each having a distinct therapeutic role.

The two main active ingredients in this preparation are the synthetic chemical substances Betamethasone Dipropionate and Gentamicin Sulfate. The highly potent nature of the Betamethasone Dipropionate component is a key feature of its glucocorticoid classification. The product is manufactured as a semi-solid cream dosage form, which is generally preferred over ointments for managing weeping or moist dermatological presentations. Betacream is exclusively a prescription medication in many regions, emphasizing its potent formulation and requiring professional oversight for appropriate use.


The Dual Purpose of Betacream's Active Ingredients

The primary purpose of Betacream is to manage inflammatory skin conditions that are either complicated by or at high risk of developing a secondary bacterial infection. This utility stems from its engineered dual action principle, which simultaneously targets both the underlying inflammation and the microbial threat.

The Betamethasone Dipropionate component provides a powerful anti-inflammatory action, rapidly suppressing immune-mediated symptoms such as intense redness, tissue swelling, and debilitating pruritus (itching). Concurrently, the Gentamicin Sulfate component exerts immediate bacterial growth control, working by inhibiting the protein synthesis essential for bacterial survival. This combination is designed to be effective against skin inflammation complicated by bacterial presence. This comprehensive approach aims to stabilize the skin condition, relieve discomfort, and promote the resolution of the dermatosis.

Regulatory References

  1. NIH DailyMed Monograph
  2. NIH DailyMed Monograph for Betamethasone Dipropionate

What side effects are possible with Betacream?

Possible Side Effects and Safety Information

The safety profile for Betacream (Betamethasone Dipropionate/Gentamicin Sulfate) is categorized by regulatory authorities into local application site reactions and risks associated with systemic absorption of the potent corticosteroid component. Reactions are grouped by System-Organ-Class (SOC) based on official documentation.


Documented Adverse Reactions

Classification Examples of Officially Listed Reactions
Common / Most Common Burning, stinging, pruritus (itching), erythema (redness), folliculitis, and vesiculation (small blisters) are noted in regulatory documents [DailyMed].
Frequency Not Known Adverse reactions reported through postmarketing surveillance include skin atrophy (thinning), striae (stretch marks), hypopigmentation, hypertrichosis, and allergic contact dermatitis [UK electronic Medicines Compendium].

Serious Adverse Reactions and Safety Constraints

Systemic risks resulting from the absorption of the potent corticosteroid component are associated with prolonged or excessive use, application to a large surface area, or use under occlusion. These serious adverse reactions documented in the Endocrine Disorders SOC include Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and manifestations of Cushing's syndrome. Ophthalmic risks such as glaucoma and cataracts are also noted from postmarketing experience [DailyMed].

  • Pediatric Vulnerability: Children are officially documented to be at a greater risk of systemic toxicity due to their higher skin surface area-to-body mass ratio, with risks including linear growth retardation.
  • Safety Restriction: The product is not for ophthalmic use, and contact with the eyes must be strictly avoided to mitigate the risk of serious ocular adverse reactions [DailyMed].

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with this topical combination product is primarily documented as a risk of systemic absorption following excessive, prolonged, or widespread use, particularly under occlusive dressings. This is based on regulatory profiles for the active ingredients, Betamethasone Dipropionate and Gentamicin Sulfate.

Documented Overdose Manifestations

Excessive systemic absorption of the high-potency corticosteroid component may lead to manifestations of Hypercorticism or Cushing's syndrome and the suppression of the hypothalamic-pituitary-adrenal (HPA) axis, resulting in Secondary Adrenal Insufficiency. Overexposure to the antibiotic component may result in officially recognized systemic toxic effects, including potential Ototoxicity (inner ear damage) and Nephrotoxicity (renal impairment).

Special Population Consideration: Pediatric patients are officially recognized as being more susceptible to systemic toxicity, including HPA axis suppression, due to their larger skin surface area-to-body weight ratio.

Emergency Actions Mandated by Regulators

If signs of systemic toxicity or adrenal suppression are observed, regulatory authorities mandate that patients seek immediate medical attention. The initial required action following a suspected overdose is the discontinuation of treatment. Management is formally described as symptomatic and supportive treatment and may involve the gradual withdrawal of the corticosteroid component to address HPA axis suppression. No specific antidote is known for the systemic effects resulting from either active ingredient.

Therapeutic Uses of Betacream

What Betacream Treats: Main Uses and Benefits

This medication is a topical combination commonly used for inflammatory skin conditions that are either complicated by a secondary bacterial infection or may be at high risk of developing one. The therapeutic indication for this combination is for secondary bacterial infections complicating pre-existing dermatoses. This combination is applied in addressing the combined symptoms common in these dermatoses, with relevant indications including secondarily infected forms of eczema, dermatitis, folliculitis, and psoriasis.


Managing Dual Symptoms and Intense Discomfort

The primary therapeutic benefit contributes to maintaining a sense of stability when symptoms are more noticeable. This is achieved by addressing symptoms related to heightened physiological activity while providing supportive antimicrobial protection to assist with managing microbial proliferation. This combination is relevant in contexts involving heightened systemic burden, such as when symptoms are moderate to severe and include pronounced redness, swelling, and intense pruritus (severe itching). Its use is relevant for episodes where these symptoms create noticeable interference with daily stability. The key benefit offers symptomatic relief that helps patients cope more steadily.

“The medication is relevant for easing challenging symptoms associated with inflammatory skin conditions complicated by bacterial presence.”

Quick Fact: Relief for Dual Discomfort
This cream is relevant for easing symptoms related to inflammatory or irritative states and those linked to microbial proliferation, supporting general well-being during symptomatic phases.

Eligibility and Restrictions for Use

Official Eligibility for Betacream (Betamethasone Topical)

This section outlines the officially documented eligibility and non-eligibility criteria for Betacream, a topical corticosteroid, based strictly on regulatory labeling (e.g., FDA, NHS).

Contraindications (Must NOT Use):

Classification Detail
Hypersensitivity Known allergy to betamethasone, other corticosteroids, or any non-active ingredient in the cream.
Skin Conditions Untreated cutaneous infections (viral, bacterial, fungal), rosacea, perioral dermatitis, or acne vulgaris.

Age and Population Restrictions:

Population Group Regulatory Status
Children le 12 Years Use is generally not recommended for certain high-potency formulations due to increased risk of systemic absorption (HPA axis suppression).
Pregnancy Use is conditional. It is recommended only if the benefit justifies the risk to the fetus, and extensive or prolonged use is discouraged.
Lactation Use with caution; it is not definitively known if systemic absorption results in detectable quantities in breast milk.

Conditional Use:

Patients with liver impairment or those applying the cream over a large surface area or under occlusive dressings are at higher risk for systemic side effects and must use the medication with increased caution as directed by a healthcare professional.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Betacream contains Betamethasone Dipropionate and Gentamicin Sulfate. Officially documented interaction patterns are predicated on the potential for significant systemic absorption of the Gentamicin Sulfate component, which increases when the cream is applied to large areas of broken skin or used under occlusive dressings.

Documented Drug-Drug Interaction Patterns

The majority of formally documented interactions are pharmacodynamic risks associated with the Gentamicin Sulfate component, based on its known systemic effects as an aminoglycoside antibiotic.

Interacting Substance/Class Formal Interaction Outcome (Documented) Type of Interaction
Neuromuscular Blocking Agents Intensifies and prolongs respiratory depressant effects. Pharmacodynamic
Oral Anticoagulants (e.g., Warfarin) Potentiates anticoagulant effect, increasing the risk of bleeding. Exposure-Altering
Potentially Neurotoxic / Nephrotoxic Drugs Risk of additive toxicity; co-administration should be avoided. Pharmacodynamic
Loop Diuretics (e.g., Furosemide) May enhance the ototoxic potential of the gentamicin component. Pharmacodynamic

Population-Dependent Interaction Cautions

The severity of interaction risks is amplified in specific patient populations, where underlying conditions may heighten susceptibility to toxicity following systemic absorption. The risk of ototoxicity from gentamicin is enhanced by renal and/or hepatic impairment. The elderly population is also noted in regulatory sources as potentially being more susceptible to aminoglycoside toxicity.

Mechanism of Action

Genomic Modulation of the Inflammatory Cascade

The Betamethasone Dipropionate component initiates its mechanism by binding to extbfGlucocorticoid Receptors inside skin cells, acting as a extbftranscription modulator. This molecular action regulates gene expression, leading to the synthesis of inhibitory proteins that indirectly block the extbfPhospholipase A2 enzyme. This suppression immediately halts the extbfArachidonic Acid Cascade, drastically limiting the body’s biological production of key pro-inflammatory mediators like prostaglandins and leukotrienes, leading to the physiological suppression of extbftissue edema and extbfimmune cell infiltration.


Targeted Inhibition of Bacterial Protein Synthesis

Concurrently, the Gentamicin Sulfate component engages a separate extbfbactericidal mechanism by extbfirreversibly binding to the extbf30S ribosomal subunit of susceptible bacteria. This interaction causes extbfmisreading of the mRNA template, leading to the manufacturing of faulty, extbfnon-functional proteins. This physiological disruption destroys the integrity and function of the bacterial cell, leading to the extbfinactivation of susceptible microbial populations.


Complementary Dual-Action Pathway Modulation

The combination mechanism is built on complementary dual-action. One active ingredient extbfmodulates the extbfhost's overactive immune pathways (anti-inflammatory action), while the other extbfinhibits the metabolic machinery of the invading bacterial extbfpathogen (antibiotic action). This integrated approach provides a coordinated action that extbfsimultaneously addresses the immune-mediated response and the microbial presence.

Dosage and Administration Information

Official Administration Guidelines

The administration of Betacream is governed by specific instructions detailing the application route, frequency, duration, and handling. The protocol is designed to ensure standardized topical use.

Feature Instruction
Route of Administration Strictly Topical (Cutaneous) only for external use.
Dosing Schedule Apply a thin film of the cream to the affected area. Maximum quantity generally restricted to 50 grams per week for the corticosteroid component.
Frequency Pattern Application is typically once daily or twice daily (e.g., morning and evening).

Use-Context and Duration

The duration of treatment is generally limited to the shortest period necessary to achieve condition control, often not exceeding two to four weeks. Therapy should be discontinued promptly once control is established.

Feature Instruction
Special Procedural Conditions The cream must be gently massaged into the skin. Use should be avoided on the face, groin, or axillae (underarms).
Use-Context Constraints Must not be used with occlusive dressings (e.g., tight bandaging) unless specifically directed by a medical professional.
Pediatric Rules Children require the minimum necessary amount for the shortest duration. Use in infants under 1 year is generally not recommended.

These guidelines define a protocol for localized application. The administration is governed by rules regarding frequency and duration, ensuring application is limited to the shortest course necessary to adhere to the established administration framework.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Clinical Trials

Research has explored the drug's effect on specific symptoms of a condition. Trials, including randomized controlled trials (RCTs), have evaluated the drug's short-term and longer-term effects compared to placebo or other evaluated options.

  • Studies have evaluated whether patient-reported quality of life is affected; other studies reported changes in measured symptom scores over the course of the study period.
  • One key study evaluated the drug's effect when administered for three months, which was explored for its effect on specific endpoints; some trials observed changes in endpoints early in the study timeline.
  • Long-term data collection has also been used to monitor the reported effect for up to two years.

Combination Therapy Studies

Several studies have evaluated this combination treatment, focusing on its two main components. The research design included looking at the effects of the combined treatment versus each component alone.

  • Research examined whether this combination affects pre-specified clinical outcomes; long-term use has been studied to gather data on outcomes over time.
  • Dosage was taken daily in the study protocol. Data reported that the combination was associated with greater changes in symptom scores compared to the single agents or placebo.

Safety and Tolerability Profile

The safety profile of the drug and the combination has been evaluated in clinical trials. Studies reported the frequency of adverse events and reasons for patient withdrawal from the trials.

  • In clinical trials, study participants reported adverse events at a monitored rate, though side effects did occur.

Ongoing and Future Research

  • In one trial, treatment continuation after symptom resolution was evaluated for its effect on long-term status.
  • Studies compared the drug to older treatments, with results varying across endpoints.
  • Preliminary data has also explored the drug's use for condition Y.
  • This method was investigated for its effect on chronic symptoms, with researchers continuing to monitor long-term outcomes in follow-up studies.

Key Studies & References

  1. Efficacy and Safety of Calcipotriene/Betamethasone Gel/Ointment in Psoriasis (Clinical Trial NCT00279162)
  2. Betamethasone topical: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing (WebMD)

Frequently Asked Questions (FAQ)

Common questions about Betacream (FAQ)

Q: Can Betacream be used on the face?

Official regulatory guidance advises against applying the cream to the face, groin, or underarms (axillae). This is often related to the skin in these areas being thinner and more susceptible to potential side effects from the potent corticosteroid component.

Q: Can Betacream cause thinning of the skin?

Yes, skin atrophy (thinning) is an adverse reaction that has been reported through postmarketing surveillance. Regulatory guidance suggests limiting use to the shortest duration necessary and applying it sparingly to the affected area to help mitigate this risk.

Q: Is Betacream safe to use during pregnancy? (informational)

Official information states that use during pregnancy is conditional. It is recommended only if the potential benefit justifies the risk to the fetus, and extensive or prolonged use is strongly discouraged. Use should be discussed with a healthcare provider.

Q: Can children use Betacream?

Regulatory documents indicate that use in infants under 1 year is generally not recommended. Official guidelines recommend that, for children le 12 years, use be limited to the minimum necessary amount for the shortest duration due to the increased risk of systemic absorption and potential adverse effects, such as linear growth retardation.

Q: What happens if I stop using Betacream suddenly?

Regulatory documents suggest that if the cream has been used for a prolonged period, stopping use may potentially result in the temporary return of the original skin condition. Regulatory information indicates that, for chronic use, gradual reduction is a common practice to potentially avoid rebound reactions.

Q: How long does the effect of one application of Betacream usually last?

The typical frequency pattern for this cream is once or twice daily application. This frequency, established by official administration guidelines, suggests that the therapeutic effect is intended to last between 12 and 24 hours per application.

Q: Can I cover the area with a bandage after applying Betacream?

Official guidance advises that the cream should not be used with occlusive dressings (e.g., tight bandaging or waterproof coverings), unless a healthcare professional specifically instructs otherwise. Occlusion can significantly increase the absorption of the active ingredients, leading to a higher risk of systemic side effects.

Q: Is Betacream available over the counter?

According to official product information and regulatory classifications, this cream is exclusively a prescription-only medication in many regions. Its potent formulation requires professional oversight for appropriate use.

Q: Will Betacream help with general itching?

Betacream is approved to treat pruritus (itching) that is associated with specific inflammatory skin conditions. The medication is intended to be used only for the conditions that a healthcare professional has diagnosed and is treating.

Q: Is it normal for my skin to feel slightly warm after applying Betacream?

Common adverse reactions noted in regulatory documents include local application site reactions such as burning, stinging, and erythema (redness). A feeling of warmth could be related to these common, usually mild, side effects.

Q: What should I do if I accidentally apply too much Betacream?

Applying an excessive amount or using it for too long can increase the risk of systemic side effects, such as HPA axis suppression. For chronic overuse, official guidance notes that management may include consulting a healthcare professional for guidance on the gradual withdrawal of the medicine, as acute symptoms are generally reversible.

Q: Will Betacream stain my clothes or bedsheets?

Safety documents recommend taking care to prevent spills and avoiding contact with clothing and linens. It is advised that any contaminated clothing should be washed before re-use, indicating the cream may potentially cause staining.

Q: Can Betacream be used on broken or scraped skin?

Regulatory guidance advises against applying the cream to skin areas that have cuts, scrapes, or burns. Regulatory guidance indicates that use on broken skin should be avoided, as this may increase the systemic absorption of the active ingredients.

Q: Is Betacream effective for reducing swelling?

Yes. The potent corticosteroid component in the cream is specifically designed to suppress symptoms of inflammation. This includes reducing physiological symptoms like tissue edema (swelling) associated with the treated skin condition.

Q: How should I clean the area before applying Betacream?

Official proper use instructions for topical medications indicate that the area to be treated should be clean and dry before the cream is applied. This practice helps ensure the proper application of the cream.

Q: Can people with sensitive skin generally tolerate Betacream?

Common adverse reactions listed in regulatory documents include local burning, stinging, and redness. These reactions suggest that some users, particularly those with pre-existing sensitive skin, may experience reduced tolerability or discomfort.

Q: What studies exist on Betacream's safety profile in different populations?

The safety profile has been evaluated in clinical trials that monitor the frequency of adverse events in participants. Official regulatory sources specifically note increased vulnerability to systemic risks in pediatric and elderly populations.

Q: Are there any documented cases of allergic reactions to Betacream?

Yes. Known hypersensitivity (allergy) to any of the ingredients is a formal contraindication for use. Additionally, allergic contact dermatitis has been reported as an adverse reaction during postmarketing surveillance.

Q: Is Betacream good for treating rashes that aren't itchy?

While the cream is known to relieve both inflammation and pruritus (itching), its core purpose is to manage inflammatory skin conditions. Therefore, its use for non-pruritic rashes depends on whether the rash involves underlying inflammation.

Q: Is Betacream considered a 'strong' or 'mild' topical steroid?

The Betamethasone Dipropionate component is officially classified as a 'potent' corticosteroid. Due to its potency, the cream requires a prescription and must be used as directed by a healthcare professional.

Q: Why is it recommended to use Betacream sparingly?

It is recommended to apply only a thin film to the affected area because the cream contains a potent corticosteroid. Excessive or prolonged use can increase the absorption of the drug through the skin, raising the risk of serious systemic side effects, such as HPA axis suppression.

How should Betacream be stored and disposed of?

Betacream (Betamethasone Dipropionate and Gentamicin Sulfate Cream) must be stored strictly according to official regulatory requirements to ensure its stability.

Storage Conditions

Storage Requirement Official Regulatory Standard
Temperature Store at Controlled Room Temperature, typically 20°C to 25°C (68°F to 77°F). Temperatures must not exceed 30°C.
Prohibited Conditions Do not freeze and protect from excessive heat.
Environmental Protection Keep in a cool, dry place, shielded from direct light and moisture.

The cream must be kept in its original container, maintained tightly closed, and stored out of the sight and reach of children.

Disposal

Expired or unused product must be handled in accordance with local requirements. Patients should consult a healthcare professional or pharmacist for guidance on proper disposal. It is required to avoid release to the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Betacream found in:

A-Z Index: